Every piece MicroCap Desk has published on Biofrontera, newest first. Independent editorial — we take no compensation from the companies we cover.
Biofrontera grew Q1 revenue 17% and had its Ameluz basal-cell-carcinoma filing accepted by the FDA. Going-concern is the catch.
Ameluz revenue growing high-teens. OpEx flat. Sales-force buildout finally scaling. The textbook commercial-stage inflection — just without the story-stock drama.
Sentiment labels reflect the Desk's directional view at the time each article was published and are not price targets, ratings, or investment advice. Microcap securities carry a high risk of loss. See our full Disclosure.